['lymphoma, large b-cell, diffuse']
['lenalidomide', 'placebo', 'rituximab', 'cyclophosphamide', 'doxorubicin', 'prednisone', 'vincristine']

        Inclusion Criteria:

          1. Histologically proven Diffuse Large B-Cell Lymphoma of the Activated B-Cell type

          2. Newly diagnosed, previously untreated Diffuse Large B-Cell Lymphoma

          3. Measurable Diffuse Large B-Cell Lymphoma disease by Computed Tomography (CT) /
             Magnetic Resonance Imagining (MRI) scans

          4. Eastern Cooperative Oncology Group (ECOG) performance status 0 - 2

          5. Age 18 - 80 years; age > 80 allowed at investigator discretion if performance status ≤
             1; and each organ system score ≤ 2 using cumulative illness rating scale (CIRS)

        Exclusion Criteria:

          1. Diagnosis of lymphoma histologies other than Diffuse Large B-Cell Lymphoma

          2. History of malignancies, other than Diffuse Large B-Cell Lymphoma, unless the patient
             has been disease free for 5 years or more

          3. Known seropositive for, or history of, active Human Immunodeficiency Virus (HIV)
             Hepatitis B Virus (HBV), Hepatitis C Virus (HCV)

          4. Contraindication to any drug in the chemotherapy regimen, and specifically: LVEF (Left
             Ventricular Ejection Fraction) < 45% or peripheral neuropathy grade 2
      